Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (46)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Teng, R.
Right arrow Articles by Harris, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teng, R.
Right arrow Articles by Harris, S. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1996) 37, 955-963
© 1996 The British Society for Antimicrobial Chemotherapy

research-article

Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers

Renli Teng, Theodore E. Liston and Stephen C. Harris

Central Research Division, Pfizer Inc. Groton, CT 06340, USA

Received 14 September 1995; accepted 30 November 1995

The multiple-dose pharmacokinetics and safety of trovafloxacin (CP-99,219), a new fluoroquinolone antibacterial agent, were evaluated in healthy male volunteers. Trovafloxacin was administered orally at 100 or 300 mg as a single dose followed by a 3 day washout period, and then was dosed once-daily for 14 consecutive days. Multiple serum and urine samples were collected on days 1 and 17 and were analysed for trovafloxacin concentrations by HPLC-UV. Following single doses, the mean Cmax values (mean±s.D.) were 1.0±0.3 and 2.9±0.4 mg/L for the 100 and 300 mg, respectively; those after 14-day consecutive daily dosing (day 17) were 1.1±0.2 and 3.3±0.5 mg/L, respectively. Trovafloxacin was rapidly absorbed and reached Cmax approximately 1 h after dosing. The mean values of T1/2 associated with the 100 and 300 mg doses were 9.2± 1.2 on day 1 and 10.5±0.7 h on day 17; those after the 300 mg doses were 10.5±1.4 and 12.2±1.9 h, respectively. The cumulative urinary recovery of unchanged drug averaged 5.3% of the administered dose. Trovafloxacin renal clearance was 0.43±0.09 L/h. The free fraction of the drug in plasma was 23.8± 6.1 %. The renal clearance, half-life and unbound fraction did not change over the course of 2 weeks of multiple dosing. Steady-state serum concentrations were attained by the third daily dose, with approximately 1.3-fold accumulation. Both doses of trovafloxacin were well tolerated, and no significant changes in any laboratory safety parameters were detected. This study shows that the pharmacokinetics of trovafloxacin are linear and stationary and that steady-state serum concentrations above the MICs for most susceptible pathogens attained.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
A. M. Noreddin, V. L. Haynes, and G. G. Zhanel
Pharmacokinetics and Pharmacodynamics of the New Quinolones
Journal of Pharmacy Practice, December 1, 2005; 18(6): 432 - 443.
[Abstract] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. D. Gootz, R. P. Zaniewski, S. L. Haskell, F. S. Kaczmarek, and A. E. Maurice
Activities of Trovafloxacin Compared with Those of Other Fluoroquinolones against Purified Topoisomerases and gyrA and grlA Mutants of Staphylococcus aureus
Antimicrob. Agents Chemother., August 1, 1999; 43(8): 1845 - 1855.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
W. Ng, I. Lutsar, L. Wubbel, F. Ghaffar, H. Jafri, G. H. McCracken, and I. R. Friedland
Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia
J. Antimicrob. Chemother., June 1, 1999; 43(6): 811 - 816.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. D. Lister and C. C. Sanders
Pharmacodynamics of Trovafloxacin, Ofloxacin, and Ciprofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model
Antimicrob. Agents Chemother., May 1, 1999; 43(5): 1118 - 1123.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
Y. S. Kim, Q. Liu, L. L. Chow, H. F. Chambers, and M. G. Täuber
Comparative Efficacy of Trovafloxacin in Experimental Endocarditis Caused by Ciprofloxacin-Sensitive, Methicillin-Resistant Staphylococcus aureus
Antimicrob. Agents Chemother., December 1, 1998; 42(12): 3325 - 3327.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
A. J. Fischman, J. W. Babich, A. A. Bonab, N. M. Alpert, J. Vincent, R. J. Callahan, J. A. Correia, and R. H. Rubin
Pharmacokinetics of [18F]Trovafloxacin in Healthy Human Subjects Studied with Positron Emission Tomography
Antimicrob. Agents Chemother., August 1, 1998; 42(8): 2048 - 2054.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
G. W. Kaatz, S. M. Seo, J. R. Aeschlimann, H. H. Houlihan, R.-C. Mercier, and M. J. Rybak
Efficacy of Trovafloxacin against Experimental Staphylococcus aureus Endocarditis
Antimicrob. Agents Chemother., February 1, 1998; 42(2): 254 - 256.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.